Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
NK

NASDAQ · NKTR

Nektar Therapeutics

Healthcare · Biotechnology

$38.87

Down-$0.31 (-0.79%)

Updated Nov 2, 2026, 4:56 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.04B
P/E ratio
-8.02
Dividend yield
0.00%
52-week range
$35.61 – $109.00
Volume
600.97K
Avg. volume
882.67K

Price performance · NKTR

NKTR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

NKTR closed at $38.87 after 20 trading sessions, down 7.93% for the selected period.

Last close
$38.87
Period change
-7.93%
Period low
$35.78
Period high
$42.22
Daily close
View OHLC price history
NKTR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$39.00$39.30$38.00$38.87600.97K
Oct 29, 2026$38.35$39.89$38.35$39.18490.3K
Oct 28, 2026$37.75$38.60$37.49$38.55405.24K
Oct 27, 2026$37.52$38.40$37.045$37.97568.31K
Oct 26, 2026$37.18$37.915$36.935$37.45532.6K
Oct 23, 2026$37.87$38.16$36.665$37.22469.62K
Oct 22, 2026$38.01$38.795$36.995$38.651.02M
Oct 21, 2026$39.09$40.35$38.25$38.27619.43K
Oct 20, 2026$36.99$39.25$36.50$39.221.06M
Oct 19, 2026$36.00$36.79$35.635$36.64831.54K
Oct 16, 2026$38.05$38.05$35.61$35.78784.3K
Oct 15, 2026$37.15$38.74$36.94$37.72684.25K
Oct 14, 2026$37.50$37.75$36.56$36.891M
Oct 13, 2026$39.79$39.83$37.75$37.922.04M
Oct 12, 2026$40.93$40.975$39.26$39.841.05M
Oct 9, 2026$40.38$42.38$40.33$41.171.17M
Oct 8, 2026$39.89$41.14$39.01$40.801.75M
Oct 7, 2026$39.22$40.35$38.445$40.261.51M
Oct 6, 2026$42.44$42.44$39.34$39.911.96M
Oct 5, 2026$43.50$43.50$41.35$42.222.03M

Latest NKTR news

The latest Smart Investors Daily articles mentioning NKTR.

Stock researchCompany · Overview

NKTR research

Overview

Company profile and research snapshot.

Company profile

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$121.00
Implied upside
—
Analysts
—
NKTR recent ratings
DateFirmRatingTarget
Oct 12, 2026UBSNeutral—
Oct 12, 2026Leerink PartnersOutperform—
Oct 9, 2026BTIGBuy—
Oct 9, 2026Raymond JamesMarket Perform—
Oct 2, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Yahoo · Oct 23, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended.

Yahoo · Oct 12, 2026

Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case

Nektar Therapeutics (NKTR) has presented new clinical data for its lead asset, rezpegaldesleukin, to dermatology specialists at the 2026 EADV Congress, highlighting long-term outcomes in atopic dermatitis and alopecia areata. Despite the fresh rezpegaldesleukin data, Nektar Therapeutics’ recent share price action has been choppy, with the stock down about 41% on a 1 month share price return and down around 39% on a 3 month share price return. At the same time, the 3 year total shareholder...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By